Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides.
Autoantibodies to ribosomal P (ribo P) are found in 15-30% of systemic lupus erythematosus (SLE) patients and are highly specific for SLE. The goal of this study is to assess the temporal association of anti-ribosomal P (anti-P) responses with SLE disease onset, as well as to characterize select humoral ribo P epitopes targeted in early, pre-diagnostic SLE samples. Patients with stored serial serum samples available prior to SLE diagnosis were identified from a military cohort. Each sample was tested for antibodies against ribo P utilizing standard C terminus ribo P enzyme-linked immunosorbent assays (ELISA) and a solid phase, bead-based assay with affinity-purified ribo P proteins. In this study, antibodies to ribo P were more common in African American SLE patients (p = 0.026), and anti-P-positive patients comprised a group with more measured autoantibody specificities than did other SLE patients (3.5 vs 2.2, p < 0.05). Antibodies against ribo P were present on average 1.7 years before SLE diagnosis and were detected an average of 1.08 years earlier in pre-diagnostic SLE samples using affinity-purified whole protein rather than C-terminal peptide alone (p = 0.0019). Furthermore, 61% of anti-P-positive patients initially had antibodies to aa 99-113, a known ribosomal P0 antigenic target, at a time point when no antibodies to the clinically used C terminus were detected. Our findings provide evidence that antibodies against ribosomal P frequently develop before clinical SLE diagnosis and are more broadly reactive than previously thought by targeting regions outside of the C terminus.
Heinlen
Latisha D
LD
Oklahoma Medical Research Foundation, 825 N.E. 13th Street, Oklahoma City, OK 73104, USA.
Ritterhouse
Lauren L
LL
McClain
Micah T
MT
Keith
Michael P
MP
Neas
Barbara R
BR
Harley
John B
JB
James
Judith A
JA
D000293:Adolescent; D000328:Adult; D001741:Black or African American; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology*; D001324:Autoantigens / Q000097:blood / Q000276:immunology*; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000276:immunology*; D012269:Ribosomal Proteins / Q000276:immunology*; D055815:Young Adult
D001323:Autoantibodies; D001324:Autoantigens; D000939:Epitopes; D010446:Peptide Fragments; D012269:Ribosomal Proteins
J Immunol Methods. 1995 Feb 27;179(2):193-202
7876567
Br J Rheumatol. 1993 Aug;32(8):663-5
8348266
N Engl J Med. 1987 Jul 30;317(5):265-71
3496538
J Rheumatol. 1991 Nov;18(11):1681-4
1787488
Lupus. 2003;12(2):99-106
12630753
Arthritis Rheum. 1999 Jan;42(1):69-75
9920016
Clin Immunol Immunopathol. 1998 Jun;87(3):292-6
9646839
Am J Med. 1995 Nov;99(5):465-72
7485202
J Mol Med (Berl). 2003 Mar;81(3):194-204
12682728
Ann Rheum Dis. 2009 Mar;68(3):412-5
18930995
Arthritis Rheum. 2008 Mar;58(3):843-53
18311802
Rheumatology (Oxford). 2002 Dec;41(12):1357-66
12468814
Clin Vaccine Immunol. 2006 Jan;13(1):77-83
16426003
J Exp Med. 1995 Feb 1;181(2):453-61
7530756
Arthritis Rheum. 2007 Jul;56(7):2344-51
17599763
Ann Rheum Dis. 2000 Dec;59(12):975-81
11087701
Nat Med. 2005 Jan;11(1):85-9
15619631
J Biol Chem. 1991 Jul 25;266(21):13815-20
1856214
Br J Rheumatol. 1997 Feb;36(2):229-33
9133936
Arthritis Rheum. 1996 Nov;39(11):1833-9
8912505
Arthritis Rheum. 1997 Sep;40(9):1725
9324032
Clin Rheumatol. 2008 Nov;27(11):1377-85
18481154
Ann N Y Acad Sci. 2005 Jun;1051:390-403
16126981
Clin Immunol Immunopathol. 1994 Aug;72(2):273-9
8050201
N Engl J Med. 2003 Oct 16;349(16):1526-33
14561795
Arthritis Rheum. 1982 Nov;25(11):1271-7
7138600
Autoimmunity. 2002 Mar;35(2):79-86
12071439
Proc Natl Acad Sci U S A. 1986 Oct;83(19):7419-23
2429305
Biometrics. 1988 Sep;44(3):837-45
3203132
Arthritis Rheum. 2006 Jan;54(1):312-24
16385548
J Autoimmun. 2009 Mar;32(2):79-84
19171463
Autoimmunity. 2005 Feb;38(1):85-92
15804709